Biolog-id LLC Expands Partnership with Hoxworth Blood Center to Further Enhance Safety and Efficiency in the Management of Blood Products Across its Enterprise
Biolog-id LLC, a developer of end-to-end blood safety solutions and a leader in connected health solutions, announced today that it’s expanding its partnership with University of Cincinnati’s Hoxworth Blood Center to include the management of Red Blood Cell Concentrates, the most commonly requested blood product, in its cutting-edge technology ecosystem across its enterprise.
The expanded partnership, aimed at improving the lives of patients requiring transfusions, leverages Biolog-id patented technology within Hoxworth facilities. The technology, Biolog-Transfusion®, tracks blood products throughout the supply chain, providing real-time visibility into inventory across locations, and collecting data, allowing for comprehensive analysis. This is the first expansion following the appointment of Troy Hilsenroth to CEO of Biolog-id LLC.
“I am thrilled to be expanding our partnership with Hoxworth Blood Center, a trusted organization within the industry, as we expand and grow Biolog-id’s North American presence,” said Troy L. Hilsenroth, CEO Biolog-id LLC. “With Hoxworth, we are committed to helping them achieve their vision by driving operational value and increasing clinical quality through our differentiated platform.”
Hoxworth Blood Center collects, tests, processes and distributes lifesaving blood to 31 hospitals and medical centers in Ohio, Kentucky and Indiana. The blood management ecosystem implemented at Hoxworth allows for the seamless addition of Red Blood Cells with a significant reduction of workload associated with the daily management of inventory and supports better data-driven decisions around the fulfilment of requests from the different hospitals.
"Our partnership with Biolog-id furthers our commitment to embracing innovative technologies to provide a reliable, safe supply of high value blood products to our patients,” said Jose A. Cancetas, Director of Hoxworth Blood Center. "The implementation of Biolog-id’s platform greatly improves the management and distribution of Platelet Concentrates and Red Blood Cell Concentrates as we look to maximize patient outcomes. We are excited for the expansion of our partnership to implement its innovative solutions across our enterprise.”
Biolog-id will be launching an additional pilot program in North America in Q4 2019 focused on the installation of its technology across another major healthcare network.
About Biolog-id
Biolog-id has developed a patented smart solution for the management and traceability of sensitive, high-value health products throughout the hospital supply chain to ensure safe delivery from donor to patient. Biolog-id operates in North America, Europe, Middle East, India and Asia Pacific region and has over 100 employees worldwide. Biolog-id is owned by its founder, managers and the Xerys Funds.
Company URL: www.biolog-id.com
About Hoxworth Blood Center
Hoxworth Blood Center, University of Cincinnati was founded in 1938 and serves 31 hospitals in 18 counties in Southwestern Ohio, Northern Kentucky and Southeastern Indiana. Annually, Hoxworth collects more than 80,000 units of blood from local donors to help save the lives of patients in area hospitals.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005037/en/
Contact information
Sothea Shreck, 212.601.3392, Sothea.Shreck@bcw-global.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Pharm Signs Strategic Trilateral Agreement with Becton Dickinson and BD Korea to Accelerate Global PFS CMO Business17.9.2025 03:00:00 EEST | Press release
Celltrion Pharm (KOSDAQ: 068706), a South Korean biopharmaceutical firm, said on September 16 that it has inked a strategic trilateral agreement with a multinational syringe manufacturer, Becton Dickinson France S.A.S. (BD), and its Korean branch BD Korea. The signing ceremony took place at Celltrion Pharm’s research center in Songdo, Incheon, with its President Yoo Young-ho in attendance alongside key officials from BD and BD Korea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250914960476/en/ From left: Jeffrey Chen, Vice President, BD (Becton Dickinson) Greater Asia; Yoo Young-ho, President, Celltrion Pharm; and Jason Hwang, Country General Manager, BD Korea, at the trilateral agreement signing ceremony. Under the three-way agreement, Celltrion Pharm will establish a long-term partnership with BD and implement joint strategies to secure global clients. By combining its advanced contract manufacturing (CMO) capabilities
Mirion Partners with IAEA to Enhance Radiation Safety on a Global Scale17.9.2025 00:19:00 EEST | Press release
Mirion (NYSE: MIR), a leading provider of advanced radiation safety solutions, has signed a partnership agreement and practical arrangements with the International Atomic Energy Agency (IAEA), the world’s central intergovernmental forum for scientific and technical cooperation in the nuclear field, to cooperate in the area of radiation detection and measurement. Through this collaboration, Mirion’s advanced instrumentation and profound understanding of ionizing radiation will combine with the IAEA’s expertise and influence to advance the safe and secure use of nuclear technology worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916693003/en/ Mirion Chairman of the Board and CEO Thomas Logan and IAEA Director General Rafael Mariano Grossi mark the signing of a partnership agreement and practical arrangements to advance radiation safety initiatives. Partnering for Public Safety The IAEA plays a vital role in facilit
NIQ and Displayce Collaborate to Bring Sales Lift Measurement to Europe’s DOOH Advertising Market16.9.2025 19:00:00 EEST | Press release
NIQ, a leading consumer intelligence company, and Displayce, a pioneering specialist technology suite for Out-of-Home advertising, are collaborating to bring advanced measurement capabilities to the European DOOH market. By combining NIQ’s trusted consumer intelligence with data from Displayce’s media activation platform, advertisers can link DOOH campaigns to in-store sales performance — driving transparency and accountability across the DOOH ecosystem. NIQ has long been a trusted source of consumer purchase insights for manufacturers and retailers, capturing the buying behavior of millions of households across more than 90 countries. Now, NIQ is extending its expertise and insights into the media ecosystem, empowering advertisers and agencies with new data assets and measurement solutions to improve their understanding of consumers and drive better ROI. Through the collaboration, NIQ and Displayce are driving the DOOH ecosystem toward more addressable, transparent, and results-driven
Andersen Consulting Expands Cybersecurity and Technology Offering with Addition of Move16.9.2025 16:30:00 EEST | Press release
Andersen Consulting has entered into a Collaboration Agreement with Move, a leader in IT infrastructure, managed services, and enterprise digital solutions with a presence in Norway and Sweden. Founded in 1989, Move provides consulting services, IT solutions, and managed services. The firm’s expertise spans cybersecurity, cloud solutions, server and storage solutions, network communications, and AI adoption. Move works with medium- and large-sized companies to design, implement, and operate secure, scalable, and future-ready IT environments. "This collaboration represents an exciting opportunity to create even greater value for our clients," said Roald Sannæs, managing director of Move. "With our capabilities and Andersen Consulting’s global reach and expertise, we can deliver more holistic solutions, helping organizations solve today’s challenges and anticipate tomorrow’s opportunities." "Move has earned a strong reputation in Norway for its technical excellence and commitment to clie
Capcom’s Resident Evil Requiem , the Latest Title in the Series, Also Coming to Nintendo Switch 2 on February 27, 2026!16.9.2025 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series scheduled for release on February 27, 2026, for PlayStation®5 system, Xbox Series X|S, and PC, will also be released for Nintendo Switch™ 2 at launch. In addition, Resident Evil 7 biohazard and Resident Evil Village, two other titles in the series, will also be released for Nintendo Switch 2 on the same date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916064724/en/ Resident Evil Requiem Key Art Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development experience cultivated over numerous hit titles. Also, at Gamescom 2025, Europe’s largest gaming trade show held in Germany in August, the title already garnered significant acclaim pri
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom